These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combined inhibition of KRAS Kitai H; Choi PH; Yang YC; Boyer JA; Whaley A; Pancholi P; Thant C; Reiter J; Chen K; Markov V; Taniguchi H; Yamaguchi R; Ebi H; Evans J; Jiang J; Lee B; Wildes D; de Stanchina E; Smith JAM; Singh M; Rosen N Nat Commun; 2024 Jul; 15(1):6076. PubMed ID: 39025835 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120 [TBL] [Abstract][Full Text] [Related]
4. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Nardi F; Perurena N; Schade AE; Li ZH; Ngo K; Ivanova EV; Saldanha A; Li C; Gokhale PC; Hata AN; Barbie DA; Paweletz CP; Jänne PA; Cichowski K J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384411 [TBL] [Abstract][Full Text] [Related]
5. Ganoderma microsporum immunomodulatory protein combined with KRAS Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909 [TBL] [Abstract][Full Text] [Related]
6. YTHDF1 Promotes Cyclin B1 Translation through m Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W Cells; 2021 Jul; 10(7):. PubMed ID: 34359836 [TBL] [Abstract][Full Text] [Related]
7. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020 [TBL] [Abstract][Full Text] [Related]
8. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159 [TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation. Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149 [TBL] [Abstract][Full Text] [Related]
10. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol. Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735 [TBL] [Abstract][Full Text] [Related]
11. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition. Barrios-Bernal P; Lucio-Lozada J; Ramos-Ramírez M; Hernández-Pedro N; Arrieta O Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901764 [TBL] [Abstract][Full Text] [Related]
12. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230 [TBL] [Abstract][Full Text] [Related]
13. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma. Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550 [TBL] [Abstract][Full Text] [Related]
14. Inhibitor of Differentiation-1 Sustains Mutant Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891 [TBL] [Abstract][Full Text] [Related]
15. IκB Kinase α Is Required for Development and Progression of Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349 [TBL] [Abstract][Full Text] [Related]
16. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway. Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131 [TBL] [Abstract][Full Text] [Related]
17. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma. Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239 [TBL] [Abstract][Full Text] [Related]
18. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570 [TBL] [Abstract][Full Text] [Related]
19. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752 [TBL] [Abstract][Full Text] [Related]